Shaw Tsen Chen

Title: Shaw Tsen Chen: Innovator in Cancer Therapy

Introduction

Shaw Tsen Chen is a notable inventor based in Taipei, Taiwan. He has made significant contributions to the field of cancer therapy through his innovative research and patented methods. His work focuses on improving treatment outcomes for cancer patients by utilizing plasma arginine levels.

Latest Patents

Shaw Tsen Chen holds a patent titled "Methods for predicting response to arginine deprivation therapy based on plasma arginine levels in cancer patients." This patent describes a method for predicting whether a cancer patient will benefit from arginine deprivation therapy. The process involves determining the plasma level of arginine in the patient and subsequently administering arginine deprivation therapy, either alone or in combination with an anti-cancer agent, based on the determined plasma level. The anti-cancer agents mentioned in the patent include FOLFOX, docetaxel, cisplatin, pemetrexed, and pembrolizumab.

Career Highlights

Shaw Tsen Chen is associated with Polaris Pharmaceuticals, Inc., where he continues to advance his research in cancer treatment. His innovative approach to therapy has the potential to enhance the effectiveness of cancer treatments and improve patient outcomes.

Collaborations

Some of his notable coworkers include Hung-Wen Chen and Hui-Fen Liu, who contribute to the collaborative efforts in research and development within the company.

Conclusion

Shaw Tsen Chen's work exemplifies the impact of innovation in the medical field, particularly in cancer therapy. His patented methods offer promising avenues for improving treatment responses in patients, showcasing the importance of research and development in healthcare.